Collectively, our preclinical and clinical data provide a strong rationale for clinical testing of dual targeting of FGFR and Akt in NSCLC patients with FGFR1-overexpressing EGFR-mutant tumors resistant to EGFR-TKI. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.